NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
NANOBIOTIX

BRIEF

published on 10/31/2024 at 08:35, 21 days 5 hours ago

NANOBIOTIX to Participate in Investor Conferences in November

Innovation Investors Healthcare Conférences NANOBIOTIX
PRESS RELEASE

published on 10/31/2024 at 08:30, 21 days 5 hours ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November
Nanobiotix to participate in multiple investor conferences in November, including Guggenheim, Stifel, and Jefferies events to discuss innovative healthcare approaches

Investor Conferences Healthcare Innovation NANOBIOTIX Nanoparticle-based Approaches Late-stage Biotechnology
BRIEF

published on 10/11/2024 at 22:20, 1 month 9 days ago

Voting Rights and Share Capital Update by Nanobiotix

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
PRESS RELEASE

published on 10/11/2024 at 22:15, 1 month 9 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix discloses voting rights and shares capital information. Find out more about the company's innovative therapeutic approaches

Voting Rights Biotechnology Shares Capital NANOBIOTIX Therapeutic Approaches
BRIEF

published on 09/18/2024 at 22:20, 2 months 2 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Revenue Increase Clinical Milestones Nanobiotix Financials NBTXR3 Progress Cash And Runway
PRESS RELEASE

published on 09/18/2024 at 22:15, 2 months 2 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
Nanobiotix updates on operational progress and reports Half Year 2024 financial results, showcasing clinical milestones and licensing agreements with Janssen. Cash reserves extended until Q4 2025

Financial Results Clinical Milestones NANOBIOTIX Half Year 2024 Janssen Agreement
BRIEF

published on 09/04/2024 at 22:20, 2 months 16 days ago

NANOBIOTIX Enhances Supervisory Board with Two Key Additions

Biotechnology Supervisory Board NANOBIOTIX Dr. Liu Anat Naschitz
PRESS RELEASE

published on 09/04/2024 at 22:15, 2 months 16 days ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
Nanobiotix announces key additions to Supervisory Board - Dr. Margaret A. Liu & Ms. Anat Naschitz. Expertise to drive growth in nanophysics-based therapies for cancer & major diseases

Supervisory Board NANOBIOTIX Dr. Margaret A. Liu Ms. Anat Naschitz Nanophysics-based Therapies
BRIEF

published on 09/03/2024 at 22:20, 2 months 17 days ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Biotechnology Webcast Fireside Chat NANOBIOTIX Investment Conference
PRESS RELEASE

published on 09/03/2024 at 22:15, 2 months 17 days ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
Nanobiotix to present at H.C. Wainwright 26th Annual Global Investment Conference. Company management to participate in fireside chat on September 11, 2024

Biotechnology Cancer H.C. Wainwright NANOBIOTIX Global Investment Conference

Accesswire

Published on 11/21/2024 at 13:30, 29 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 29 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 59 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 59 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 59 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 44 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 24 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 44 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 52 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 59 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 39 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE